title: Linagliptin: A thorough Characterization beyond Its Clinical Efficacy.
abstract: Linagliptin, one of the five dipeptidyl peptidase-4 inhibitors available, has recently entered the market both in the US and in most European countries for treatment of type 2 diabetes mellitus. It presents a xanthine-based structure, and is characterized by unique pharmacokinetics, with non-linear profile, long terminal half-life allowing prolonged exposure to the drug. It is eliminated predominately through the intestinal tract and only minimally into urine, so that it can be administered, without any dose adjustment, in conditions of renal impairment. Linagliptin is effective in modifying all parameters of hyperglycemia either in monotherapy, or as add-on therapy, together with metformin or a sulfonylurea. It also exhibits a good tolerability profile with few side effects, absence (when used in monotherapy), or low risk (when in combination with a sulfonylurea) of hypoglycemia. More importantly it has a weight neutral effect. A comprehensive report of the literature on linagliptin is provided, paying attention in particular to preclinical studies, interactions with other drugs, safety and tolerability, and results obtained in animal models that highlight properties of linagliptin suggestive of potential additional uses. Particularly promising appear the data demonstrating a positive effect of linagliptin on metabolic dysfunction and renal and/or cardiovascular damage together with more recently reported effects of linagliptin on tissue repair and neuroprotection.
authors.affiliation: Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania Catania, Italy.
authors.forename: Maria Angela
authors.initials: MA
authors.lastname: Sortino
authors.forename: Tiziana
authors.initials: T
authors.lastname: Sinagra
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Canonico
keywords: DPP-4 inhibitors; GLP-1; anti-diabetic drugs; diabetes mellitus; incretin
references.citation: J Clin Pharmacol. 2008 Oct;48(10):1171-8
references.pmid: 18812608
references.citation: Diabetes Obes Metab. 2011 Jul;13(7):653-61
references.pmid: 21410628
references.citation: Int J Clin Pharmacol Ther. 2011 May;49(5):300-10
references.pmid: 21543033
references.citation: Diabetes Obes Metab. 2012 Apr;14(4):348-57
references.pmid: 22145698
references.citation: Drug Metab Pharmacokinet. 2011;26(2):123-9
references.pmid: 21084763
references.citation: Diabetes Obes Metab. 2012 Dec;14(12):1145-54
references.pmid: 22974280
references.citation: Biochim Biophys Acta. 2008 Sep;1784(9):1130-45
references.pmid: 18262497
references.citation: Diabetes Obes Metab. 2011 Mar;13(3):258-67
references.pmid: 21205122
references.citation: Diabet Med. 2010 Dec;27(12):1409-19
references.pmid: 21059094
references.citation: Diabetes Obes Metab. 2009 Aug;11(8):786-94
references.pmid: 19476474
references.citation: Drug Metab Dispos. 2013 Jan;41(1):149-58
references.pmid: 23073734
references.citation: Clin Drug Investig. 2011;31(9):643-53
references.pmid: 21714581
references.citation: Bioorg Med Chem Lett. 2007 Jul 15;17(14):3877-9
references.pmid: 17502141
references.citation: J Pharmacol Exp Ther. 2008 Apr;325(1):175-82
references.pmid: 18223196
references.citation: Int J Cardiol. 2013 Jul 15;167(1):87-93
references.pmid: 22217485
references.citation: Expert Opin Pharmacother. 2011 Dec;12(17):2759-62
references.pmid: 21883034
references.citation: Cardiovasc Res. 2012 Oct 1;96(1):140-9
references.pmid: 22843705
references.citation: Diabetes. 2013 Apr;62(4):1289-96
references.pmid: 23209191
references.citation: PLoS One. 2012;7(6):e38744
references.pmid: 22761701
references.citation: J Endocrinol. 2012 Sep;214(3):381-7
references.pmid: 22761275
references.citation: Diabetes Obes Metab. 2012 May;14(5):470-8
references.pmid: 22268497
references.citation: Curr Med Res Opin. 2009 Aug;25(8):1963-72
references.pmid: 19552619
references.citation: Br J Clin Pharmacol. 2011 Jul;72(1):39-50
references.pmid: 21306414
references.citation: J Clin Endocrinol Metab. 2013 Jul;98(7):E1163-72
references.pmid: 23633194
references.citation: Diabet Med. 2011 Nov;28(11):1352-61
references.pmid: 21781152
references.citation: J Med Chem. 2007 Dec 27;50(26):6450-3
references.pmid: 18052023
references.citation: Diabetes Obes Metab. 2012 Jun;14(6):565-74
references.pmid: 22356132
references.citation: Br J Clin Pharmacol. 2012 Jul;74(1):75-85
references.pmid: 22242621
references.citation: Int J Clin Pharmacol Ther. 2010 Jun;48(6):367-74
references.pmid: 20497745
references.citation: Diabetes Obes Metab. 2011 Oct;13(10):939-46
references.pmid: 21672124
references.citation: Diabetes Obes Metab. 2011 Jan;13(1):7-18
references.pmid: 21114598
references.citation: Eur J Pharm Sci. 2012 Apr 11;45(5):533-8
references.pmid: 22198311
references.citation: Kidney Blood Press Res. 2012;36(1):119-30
references.pmid: 23171828
references.citation: Diabetes Obes Metab. 2011 Jan;13(1):65-74
references.pmid: 21114605
references.citation: J Pharmacol Exp Ther. 2012 Jul;342(1):71-80
references.pmid: 22493041
references.citation: Clin Ther. 2011 Aug;33(8):1096-103
references.pmid: 21803422
references.citation: Biopharm Drug Dispos. 2009 Jul;30(5):229-40
references.pmid: 19562682
references.citation: J Pharm Pharmacol. 2009 Jan;61(1):55-62
references.pmid: 19126297
references.citation: Clin Lab. 2012;58(7-8):787-99
references.pmid: 22997980
references.citation: Gastroenterology. 2007 May;132(6):2131-57
references.pmid: 17498508
references.citation: Curr Mol Med. 2012 Sep;12(8):995-1004
references.pmid: 22804249
references.citation: Kidney Blood Press Res. 2012;36(1):65-84
references.pmid: 22947920
references.citation: Drug Metab Dispos. 2010 Sep;38(9):1443-8
references.pmid: 20538719
references.citation: Clin Endocrinol (Oxf). 2012 Oct;77(4):489-99
references.pmid: 22804841
references.citation: Cardiovasc Diabetol. 2012 Jan 10;11:3
references.pmid: 22234149
references.citation: Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):17-24
references.pmid: 21340661
references.citation: J Pharmacol Exp Ther. 2009 Feb;328(2):556-63
references.pmid: 18971371
references.citation: Diabetes Obes Metab. 2012 Nov;14(11):1050-3
references.pmid: 22651241
references.citation: Diabetes Obes Metab. 2011 Jun;13(6):542-50
references.pmid: 21352464
references.citation: Biopharm Drug Dispos. 2009 Nov;30(8):422-36
references.pmid: 19771584
references.citation: Int J Clin Pharmacol Ther. 2010 Oct;48(10):652-61
references.pmid: 20875371